The efficacy of tissue factor pathway inhibitor (TFPI) as topically applied antithrombotic agent
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
The efficacy of tissue factor pathway inhibitor (TFPI) as topically applied antithrombotic agent. / Aagaard, Susanne; Hjortdal, Vibeke E; Barker, John H.
In: A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica, No. 109, 2003, p. 102-7.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The efficacy of tissue factor pathway inhibitor (TFPI) as topically applied antithrombotic agent
AU - Aagaard, Susanne
AU - Hjortdal, Vibeke E
AU - Barker, John H
PY - 2003
Y1 - 2003
N2 - Tissue factor pathway inhibitor (TFPI) acts by complexing with tissue factor and factors VIIa and Xa to retard the extrinsic pathway of the coagulative process. The present study was designed to assess the antithrombotic properties of topically applied TFPI in a model of rabbit arterial thrombosis. A standardised, thrombogenic end-to-end anastomosis was made on the central ear artery. The anastomotic site was irrigated with vehicle (control, n = 5), TFPI 4 micrograms/ml (n = 8), TFPI 40 micrograms/ml (n = 8), or heparin 100 IE/ml (n = 7). The growing thrombus was observed under a stereo microscope. The image was displayed on a video monitor and recorded for analysis using computer assisted planimetry. Topical application of TFPI in either concentration or heparin did not change maximal thrombus size, mean thrombus size, or time to maximal thrombus size significantly when compared to the contralateral vehicle-treated ear. Significant anastomotic bleeding was observed in vessels treated with TFPI 40 micrograms/ml (p < 0.05).
AB - Tissue factor pathway inhibitor (TFPI) acts by complexing with tissue factor and factors VIIa and Xa to retard the extrinsic pathway of the coagulative process. The present study was designed to assess the antithrombotic properties of topically applied TFPI in a model of rabbit arterial thrombosis. A standardised, thrombogenic end-to-end anastomosis was made on the central ear artery. The anastomotic site was irrigated with vehicle (control, n = 5), TFPI 4 micrograms/ml (n = 8), TFPI 40 micrograms/ml (n = 8), or heparin 100 IE/ml (n = 7). The growing thrombus was observed under a stereo microscope. The image was displayed on a video monitor and recorded for analysis using computer assisted planimetry. Topical application of TFPI in either concentration or heparin did not change maximal thrombus size, mean thrombus size, or time to maximal thrombus size significantly when compared to the contralateral vehicle-treated ear. Significant anastomotic bleeding was observed in vessels treated with TFPI 40 micrograms/ml (p < 0.05).
KW - Administration, Topical
KW - Animals
KW - Anticoagulants/administration & dosage
KW - Blood Vessels/injuries
KW - Lipoproteins/administration & dosage
KW - Male
KW - Rabbits
KW - Thromboplastin/antagonists & inhibitors
KW - Thrombosis/drug therapy
M3 - Journal article
C2 - 12874959
SP - 102
EP - 107
JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
SN - 0903-4641
IS - 109
ER -
ID: 243519286